Minoxidil and its use in hair disorders: a review

References

• Campese VM. Minoxidil: a review of its pharmacological properties and therapeutic use. Drugs. 1981;22(4):257–278. doi:10.2165/00003495-198122040-000017030707
   PubMed Web of Science ®Google Scholar
• Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130–136.22409453
   PubMedGoogle Scholar
• Tata S, Weiner N, Flynn G. Relative influence of ethanol and propylene glycol cosolvents on deposition of minoxidil into the skin. J Pharm Sci. 1994;83(10):1508–1510. doi:10.1002/jps.26008310267884676
   PubMed Web of Science ®Google Scholar
• Gogtay JA, Panda M. Minoxidil topical foam: a new kid on the block. Int J Trichology. 2009;1(2):142. doi:10.4103/0974-7753.5856020927239
   PubMedGoogle Scholar
• Purnak T, Senel E, Sahin C. Liquid formulation of minoxidil versus its foam formulation. Indian J Dermatol. 2011;56(4):462. doi:10.4103/0019-5154.8471421965875
   PubMedGoogle Scholar
• Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. Faseb J. 2008;22(6):1725–1736. doi:10.1096/fj.07-09942418258787
   PubMed Web of Science ®Google Scholar
• Xu D, Wang L, Dai W, Lu L. A requirement for K+-channel activity in growth factor-mediated extracellular signal-regulated kinase activation in human myeloblastic leukemia ML-1 cells. Blood. 1999;94(1):139–145.10381506
   PubMed Web of Science ®Google Scholar
• Malhi H, Irani AN, Rajvanshi P, et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem. 2000;275(34):26050–26057.10862612
   PubMed Web of Science ®Google Scholar
• Buhl AE, Waldon DJ, Kawabe TT, Holland JM. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989;92(3):315–320.2465357
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Kudlacek PE, Clemens DL. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998;109(1–3):53–67.9566733
   PubMed Web of Science ®Google Scholar
• Goren A, Sharma A, Dhurat R, et al. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018;31(6):e12741. doi:10.1111/dth.1274130226287
   PubMed Web of Science ®Google Scholar
• Lowenthal DT, Affrime MB. Pharmacology and pharmacokinetics of minoxidil. J Cardiovasc Pharmacol. 1980;2 Suppl 2:S93–S106. doi:10.1097/00005344-198000022-000026156363
   PubMed Web of Science ®Google Scholar
• Mori O, Uno H. The effect of topical minoxidil on hair follicular cycles of rats. J Dermatol. 1990;17(5):276–281.2380431
   PubMedGoogle Scholar
• Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41(5 Pt 1):717–721. doi:10.1016/s0190-9622(99)70006-x10534633
   PubMed Web of Science ®Google Scholar
• Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–385. doi:10.1067/mjd.2002.12408812196747
   PubMed Web of Science ®Google Scholar
• Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–194. doi:10.1111/j.1365-2133.2004.05785.x14996087
   PubMed Web of Science ®Google Scholar
• Abell E. Histologic response to topically applied minoxidil in male-pattern alopecia. Clin Dermatol. 1988;6(4):191–194.3214821
   PubMed Web of Science ®Google Scholar
• Headington IT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res 1984;36:1098–1106.
   Google Scholar
• Sakita S, Kagoura M, Toyoda M, Morohashi M. The induction by topical minoxidil of increased fenestration in the perifollicular capillary wall. Br J Dermatol. 1999;140(2):294–296. doi:10.1046/j.1365-2133.1999.02666.x10233226
   PubMed Web of Science ®Google Scholar
• Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407–411. doi:10.1046/j.1365-2133.1998.02115.x9580790
   PubMed Web of Science ®Google Scholar
• Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409–417. doi:10.1172/JCI1131711181640
   PubMed Web of Science ®Google Scholar
• Yum S, Jeong S, Kim D, et al. Minoxidil Induction of VEGF is mediated by inhibition of HIF-Prolyl hydroxylase. Int J Mol Sci. 2017;19(1). doi:10.3390/ijms19010053
   PubMed Web of Science ®Google Scholar
• Michelet JF, Commo S, Billoni N, Mahe YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108(2):205–209. doi:10.1111/1523-1747.ep123342499008235
   PubMed Web of Science ®Google Scholar
• Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1988;37(5):867–874. doi:10.1016/0006-2952(88)90174-83278714
   PubMed Web of Science ®Google Scholar
• Shin H, Kwack MH, Shin SH, et al. Identification of transcriptional targets of Wnt/beta-catenin signaling in dermal papilla cells of human scalp hair follicles: EP2 is a novel transcriptional target of Wnt3a. J Dermatol Sci. 2010;58(2):91–96. doi:10.1016/j.jdermsci.2010.02.01120347274
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–2263. doi:10.1111/jdv.1517129972712
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. Am J Clin Dermatol. 2019;20(1):147–153. doi:10.1007/s40257-018-0387-030206824
   PubMed Web of Science ®Google Scholar
• Rojhirunsakool S, Suchonwanit P. Parietal scalp is another affected area in female pattern hair loss: an analysis of hair density and hair diameter. Clin Cosmet Investig Dermatol. 2018;11:7–12. doi:10.2147/CCID.S153768
   PubMed Web of Science ®Google Scholar
• Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med. 2001;7(7):293–301.11425637
   PubMed Web of Science ®Google Scholar
• Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–141.e135. doi:10.1016/j.jaad.2017.02.05428396101
   PubMed Web of Science ®Google Scholar
• Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643–646. doi:10.1016/0190-9622(90)70089-z2180995
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767–774. doi:10.1016/j.jaad.2007.04.01217761356
   PubMed Web of Science ®Google Scholar
• Berger RS, Fu JL, Smiles KA, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003;149(2):354–362. doi:10.1046/j.1365-2133.2003.05435.x12932243
   PubMed Web of Science ®Google Scholar
• Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541–553. doi:10.1016/j.jaad.2003.06.01415034503
   PubMed Web of Science ®Google Scholar
• Tsuboi R, Tanaka T, Nishikawa T, et al. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Eur J Dermatol. 2007;17(1):37–44. doi:10.1684/ejd.2007.018717324826
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126–1134.e1122. doi:10.1016/j.jaad.2010.09.72421700360
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U, Shapiro J, Messenger AG, et al. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a Phase III, randomized, investigator-blinded study. J Drugs Dermatol. 2016;15(7):883–889.27391640
   PubMed Web of Science ®Google Scholar
• Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs. 2016;76(14):1349–1364. doi:10.1007/s40265-016-0629-527554257
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776–789. doi:10.1542/peds.108.3.776
   Google Scholar
• Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014;27(4):252–254. doi:10.1111/dth.1213024773771
   PubMed Web of Science ®Google Scholar
• Goren A, Shapiro J, Roberts J, et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatol Ther. 2015;28(1):13–16. doi:10.1111/dth.1216425112173
   PubMed Web of Science ®Google Scholar
• Goren A, McCoy J, Kovacevic M, et al. The effect of topical minoxidil treatment on follicular sulfotransferase enzymatic activity. J Biol Regul Homeost Agents. 2018;32(4):937–940.30043580
   PubMed Web of Science ®Google Scholar
• McCoy J, Goren A, Kovacevic M, Shapiro J. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents. 2016;30(4):1153–1155.28078868
   PubMed Web of Science ®Google Scholar
• Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014;27(3):171–173. doi:10.1111/dth.1211124283387
   PubMed Web of Science ®Google Scholar
• Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152–1161. doi:10.1016/j.addr.2007.07.00417889400
   PubMed Web of Science ®Google Scholar
• Dias PCR, Miot HA, Trueb RM, Ramos PM. Use of minoxidil sulfate versus minoxidil base in androgenetic alopecia treatment: friend or foe? Skin Appendage Disord. 2018;4(4):349–350. doi:10.1159/00048801130410915
   PubMed Web of Science ®Google Scholar
• Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–109. doi:10.1111/ijd.1383829231239
   PubMed Web of Science ®Google Scholar
• Sriphojanart T, Khunkhet S, Suchonwanit P. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata. Dermatol Rep. 2017;9(2):7399. doi:10.4081/dr.2017.7399
   PubMed Web of Science ®Google Scholar
• Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323–2335. doi:10.2147/DDDT.S172638
   PubMed Web of Science ®Google Scholar
• Gupta AK, Carviel J, Abramovits W. Treating alopecia areata: current practices versus new directions. Am J Clin Dermatol. 2017;18(1):67–75. doi:10.1007/s40257-016-0230-427770310
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24. doi:10.1016/j.jaad.2017.04.114229241773
   PubMed Web of Science ®Google Scholar
• Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):730–736. doi:10.1016/s0190-9622(87)70095-43549809
   PubMed Web of Science ®Google Scholar
• Price VH. Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. J Am Acad Dermatol. 1987;16(3 Pt 2):737–744. doi:10.1016/s0190-9622(87)70096-63549810
   PubMed Web of Science ®Google Scholar
• Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987;16(3 Pt 2):745–748. doi:10.1016/s0190-9622(87)80003-83549811
   PubMed Web of Science ®Google Scholar
• Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128(11):1467–1473.1444500
   PubMedGoogle Scholar
• Weiss VC, West DP. Topical minoxidil therapy and hair regrowth. Arch Dermatol. 1985;121(2):191–192.3977331
   PubMedGoogle Scholar
• Fiedler VC, Buys CM. Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. Dermatologica. 1987;175 Suppl 2:29–35.
   PubMedGoogle Scholar
• Ranchoff RE, Bergfeld WF, Steck WD, Subichin SJ. Extensive alopecia areata. Results of treatment with 3% topical minoxidil. Cleve Clin J Med. 1989;56(2):149–154.2659203
   PubMed Web of Science ®Google Scholar
• Khoury EL, Price VH, Abdel-Salam MM, Stern M, Greenspan JS. Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. J Invest Dermatol. 1992;99(1):40–47. doi:10.1111/1523-1747.ep126114091607678
   PubMed Web of Science ®Google Scholar
• Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol. 1987;123(11):1488–1490.3674909
   PubMedGoogle Scholar
• Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27(5):385–389.
   Web of Science ®Google Scholar
• Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. F1000Res. 2017;6:1650. doi:10.12688/f1000research.10493.229167734
   PubMedGoogle Scholar
• Harnchoowong S, Suchonwanit P. PPAR-gamma agonists and their role in primary cicatricial alopecia. PPAR Res. 2017;2017:2501248. doi:10.1155/2017/250124829333153
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Hector CE, Bin Saif GA, McMichael AJ. Factors affecting the severity of central centrifugal cicatricial alopecia. Int J Dermatol. 2016;55(6):e338–e343.26769173
   PubMed Web of Science ®Google Scholar
• Eginli A, Dothard E, Bagayoko CW, Huang K, Daniel A, McMichael AJ. A retrospective review of treatment results for patients with central centrifugal cicatrical alopecia. J Drugs Dermatol. 2017;16(4):317–320.28403264
   PubMed Web of Science ®Google Scholar
• Fertig R, Tosti A. Frontal fibrosing alopecia treatment options. Intractable Rare Dis Res. 2016;5(4):314–315.27904832
   PubMedGoogle Scholar
• Tosti A, Piraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005;52(1):55–60.15627081
   PubMed Web of Science ®Google Scholar
• Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol. 2007;21(3):433–434.17309495
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, McMichael AJ. Alopecia in association with malignancy: a review. Am J Clin Dermatol. 2018;19(6):853–865.30088232
   PubMed Web of Science ®Google Scholar
• Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35(1):74–78.8682968
   PubMed Web of Science ®Google Scholar
• Granai CO, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Eur J Gynaecol Oncol. 1991;12(2):129–132.2055226
   PubMedGoogle Scholar
• Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin–induced alopecia. Ann Oncol. 1994;5(8):769–770.7826913
   PubMed Web of Science ®Google Scholar
• Prevezas C, Matard B, Pinquier L, Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol. 2009;160(4):883–885.19222453
   PubMed Web of Science ®Google Scholar
• Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. Australas J Dermatol. 2016;57(4):e130–e132.25966934
   PubMed Web of Science ®Google Scholar
• Djabali K, Panteleyev AA, Lalin T, et al. Recurrent missense mutations in the hair keratin gene hHb6 in monilethrix. Clin Exp Dermatol. 2003;28(2):206–210.12653715
   PubMed Web of Science ®Google Scholar
• Rossi A, Iorio A, Scali E, et al. Monilethrix treated with minoxidil. Int J Immunopathol Pharmacol. 2011;24(1):239–242.21496408
   PubMed Web of Science ®Google Scholar
• Chandran NS, Oranje AP. Minoxidil 5% solution for topical treatment of loose anagen hair syndrome. Pediatr Dermatol. 2014;31(3):389–390.24602086
   PubMed Web of Science ®Google Scholar
• Sinclair R. Treatment of monilethrix with oral minoxidil. JAAD Case Rep. 2016;2(3):212–215.27284572
   PubMedGoogle Scholar
• Cranwell WC, Sinclair R. Loose anagen hair syndrome: treatment with systemic minoxidil characterised by marked hair colour change. Australas J Dermatol. 2018;59(4):e286–e287.29566258
   PubMed Web of Science ®Google Scholar
• Chanasumon N, Sriphojanart T, Suchonwanit P. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis. Drug Des Devel Ther. 2018;12:365–372.
   PubMed Web of Science ®Google Scholar
• Suchonwanit P, Chanasumon N, Sriphojanart T. Efficacy and safety of bimatoprost 0.01% for the treatment of eyebrow hypotrichosis: a randomized, double-blind, vehicle-controlled study. Dermatol Surg. 2019. doi:10.1097/DSS.0000000000001944
   PubMed Web of Science ®Google Scholar
• Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol. 2014;41(2):149–152.24471459
   PubMed Web of Science ®Google Scholar
• Worapunpong N, Tanglertsampan C. Treatment of eyebrow hypotrichosis with 1% minoxidil lotion: a prospective, randomized, double-blind, placebo-controlled trial. J Med Assoc Thai. 2017;100(5):574–577.
   Google Scholar
• Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol. 2012;39(10):865–866.22594928
   PubMed Web of Science ®Google Scholar
• Ingprasert S, Tanglertsampan C, Tangphianphan N, Reanmanee C. Efficacy and safety of minoxidil 3% lotion for beard enhancement: a randomized, double-masked, placebo-controlled study. J Dermatol. 2016;43(8):968–969.26893270
   PubMed Web of Science ®Google Scholar
• Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309–312.11807448
   PubMed Web of Science ®Google Scholar
• Dawber RP, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol. 2003;17(3):271–275.12702063
   PubMed Web of Science ®Google Scholar
• Peluso AM, Misciali C, Vincenzi C, Tosti A. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol. 1997;136(1):118–120.9039309
   PubMed Web of Science ®Google Scholar
• Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–566; quiz 567–548.18793935
   PubMed Web of Science ®Google Scholar
• Earhart RN, Ball J, Nuss DD, Aeling JL. Minoxidil-induced hypertrichosis: treatment with calcium thioglycolate depilatory. South Med J. 1977;70(4):442–443.850811
   PubMed Web of Science ®Google Scholar